Early conversion to belatacept after renal transplantation

Vinay Nair, Luz E. Liriano-Ward, Rebecca Kent, Shirish Huprikar, Mena Rana, Sander S. Florman, Veronica B. Delaney, Madhav C. Menon, Vinita Sehgal, Leandra Miko, Rafael Khaim, Alan Benvenisty, Susan Lerner, Antonios Arvelakis, Vikram Wadhera, Scott Ames, Ron Shapiro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Belatacept is a non-nephrotoxic immunosuppressive agent, which may make it the ideal agent for patients with delayed or slow graft function on calcineurin inhibitors. There are limited data on conversion of patients to belatacept within 6 months of transplantation. Between January 2012 and December 2015, 16 patients were converted to belatacept for delayed or poor graft function (eGFR<30 mL/min/1.73 m2, MDRD); three were HIV positive. Conversion protocols were analyzed in patients ≤4 months and 4-6 months post-transplantation. Mean serum creatinine levels after belatacept conversion were compared with preconversion levels. Patient survival was 100%, and graft survival was 88%. The mean creatinine fell from 3.9±1.82 mg/dL prebelatacept conversion to 2.1±1.1 mg/dL at 6 months and 1.9±0.47 mg/dL (median 1.8 mg/dL) at 12 months postconversion. There was no significant increased risk of rejection, infection, or malignancy. HIV parameters remained largely stable. Early conversion to belatacept in patients with DGF or slow graft function is safe and efficacious, in a single-center nonrandomized retrospective analysis.

Original languageEnglish (US)
Article numbere12951
JournalClinical Transplantation
Volume31
Issue number5
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Kidney Transplantation
Transplants
Creatinine
Transplantation
HIV
Proxy
Graft Survival
Immunosuppressive Agents
Abatacept
Survival
Infection
Serum
Neoplasms

Keywords

  • belatacept
  • delayed graft function
  • HIV
  • immunosuppression
  • kidney transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Nair, V., Liriano-Ward, L. E., Kent, R., Huprikar, S., Rana, M., Florman, S. S., ... Shapiro, R. (2017). Early conversion to belatacept after renal transplantation. Clinical Transplantation, 31(5), [e12951]. https://doi.org/10.1111/ctr.12951

Early conversion to belatacept after renal transplantation. / Nair, Vinay; Liriano-Ward, Luz E.; Kent, Rebecca; Huprikar, Shirish; Rana, Mena; Florman, Sander S.; Delaney, Veronica B.; Menon, Madhav C.; Sehgal, Vinita; Miko, Leandra; Khaim, Rafael; Benvenisty, Alan; Lerner, Susan; Arvelakis, Antonios; Wadhera, Vikram; Ames, Scott; Shapiro, Ron.

In: Clinical Transplantation, Vol. 31, No. 5, e12951, 01.05.2017.

Research output: Contribution to journalArticle

Nair, V, Liriano-Ward, LE, Kent, R, Huprikar, S, Rana, M, Florman, SS, Delaney, VB, Menon, MC, Sehgal, V, Miko, L, Khaim, R, Benvenisty, A, Lerner, S, Arvelakis, A, Wadhera, V, Ames, S & Shapiro, R 2017, 'Early conversion to belatacept after renal transplantation', Clinical Transplantation, vol. 31, no. 5, e12951. https://doi.org/10.1111/ctr.12951
Nair, Vinay ; Liriano-Ward, Luz E. ; Kent, Rebecca ; Huprikar, Shirish ; Rana, Mena ; Florman, Sander S. ; Delaney, Veronica B. ; Menon, Madhav C. ; Sehgal, Vinita ; Miko, Leandra ; Khaim, Rafael ; Benvenisty, Alan ; Lerner, Susan ; Arvelakis, Antonios ; Wadhera, Vikram ; Ames, Scott ; Shapiro, Ron. / Early conversion to belatacept after renal transplantation. In: Clinical Transplantation. 2017 ; Vol. 31, No. 5.
@article{149cd4ebfd1b4a66a43da3141a72d03f,
title = "Early conversion to belatacept after renal transplantation",
abstract = "Belatacept is a non-nephrotoxic immunosuppressive agent, which may make it the ideal agent for patients with delayed or slow graft function on calcineurin inhibitors. There are limited data on conversion of patients to belatacept within 6 months of transplantation. Between January 2012 and December 2015, 16 patients were converted to belatacept for delayed or poor graft function (eGFR<30 mL/min/1.73 m2, MDRD); three were HIV positive. Conversion protocols were analyzed in patients ≤4 months and 4-6 months post-transplantation. Mean serum creatinine levels after belatacept conversion were compared with preconversion levels. Patient survival was 100{\%}, and graft survival was 88{\%}. The mean creatinine fell from 3.9±1.82 mg/dL prebelatacept conversion to 2.1±1.1 mg/dL at 6 months and 1.9±0.47 mg/dL (median 1.8 mg/dL) at 12 months postconversion. There was no significant increased risk of rejection, infection, or malignancy. HIV parameters remained largely stable. Early conversion to belatacept in patients with DGF or slow graft function is safe and efficacious, in a single-center nonrandomized retrospective analysis.",
keywords = "belatacept, delayed graft function, HIV, immunosuppression, kidney transplantation",
author = "Vinay Nair and Liriano-Ward, {Luz E.} and Rebecca Kent and Shirish Huprikar and Mena Rana and Florman, {Sander S.} and Delaney, {Veronica B.} and Menon, {Madhav C.} and Vinita Sehgal and Leandra Miko and Rafael Khaim and Alan Benvenisty and Susan Lerner and Antonios Arvelakis and Vikram Wadhera and Scott Ames and Ron Shapiro",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/ctr.12951",
language = "English (US)",
volume = "31",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Early conversion to belatacept after renal transplantation

AU - Nair, Vinay

AU - Liriano-Ward, Luz E.

AU - Kent, Rebecca

AU - Huprikar, Shirish

AU - Rana, Mena

AU - Florman, Sander S.

AU - Delaney, Veronica B.

AU - Menon, Madhav C.

AU - Sehgal, Vinita

AU - Miko, Leandra

AU - Khaim, Rafael

AU - Benvenisty, Alan

AU - Lerner, Susan

AU - Arvelakis, Antonios

AU - Wadhera, Vikram

AU - Ames, Scott

AU - Shapiro, Ron

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Belatacept is a non-nephrotoxic immunosuppressive agent, which may make it the ideal agent for patients with delayed or slow graft function on calcineurin inhibitors. There are limited data on conversion of patients to belatacept within 6 months of transplantation. Between January 2012 and December 2015, 16 patients were converted to belatacept for delayed or poor graft function (eGFR<30 mL/min/1.73 m2, MDRD); three were HIV positive. Conversion protocols were analyzed in patients ≤4 months and 4-6 months post-transplantation. Mean serum creatinine levels after belatacept conversion were compared with preconversion levels. Patient survival was 100%, and graft survival was 88%. The mean creatinine fell from 3.9±1.82 mg/dL prebelatacept conversion to 2.1±1.1 mg/dL at 6 months and 1.9±0.47 mg/dL (median 1.8 mg/dL) at 12 months postconversion. There was no significant increased risk of rejection, infection, or malignancy. HIV parameters remained largely stable. Early conversion to belatacept in patients with DGF or slow graft function is safe and efficacious, in a single-center nonrandomized retrospective analysis.

AB - Belatacept is a non-nephrotoxic immunosuppressive agent, which may make it the ideal agent for patients with delayed or slow graft function on calcineurin inhibitors. There are limited data on conversion of patients to belatacept within 6 months of transplantation. Between January 2012 and December 2015, 16 patients were converted to belatacept for delayed or poor graft function (eGFR<30 mL/min/1.73 m2, MDRD); three were HIV positive. Conversion protocols were analyzed in patients ≤4 months and 4-6 months post-transplantation. Mean serum creatinine levels after belatacept conversion were compared with preconversion levels. Patient survival was 100%, and graft survival was 88%. The mean creatinine fell from 3.9±1.82 mg/dL prebelatacept conversion to 2.1±1.1 mg/dL at 6 months and 1.9±0.47 mg/dL (median 1.8 mg/dL) at 12 months postconversion. There was no significant increased risk of rejection, infection, or malignancy. HIV parameters remained largely stable. Early conversion to belatacept in patients with DGF or slow graft function is safe and efficacious, in a single-center nonrandomized retrospective analysis.

KW - belatacept

KW - delayed graft function

KW - HIV

KW - immunosuppression

KW - kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=85018557533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018557533&partnerID=8YFLogxK

U2 - 10.1111/ctr.12951

DO - 10.1111/ctr.12951

M3 - Article

C2 - 28267882

AN - SCOPUS:85018557533

VL - 31

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5

M1 - e12951

ER -